Home / Resource Library / Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and > 2 prior therapies: Pivotal phase II expansion results
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and > 2 prior therapies: Pivotal phase II expansion results